Skip to main content

Advertisement

Table 1 Composition of the panel and results of the pre-release testing and of the study

From: External quality assessment of cytomegalovirus DNA detection on dried blood spots

      Correct qualitative results
      PCR
   Pre-release testing: qualitative results on DBS Conventional Real-time Total results
n = 33
n(%)
SAMPLE Target sample concentration (copies/ml) MI1 UT12 UT22 In-house n = 5 n (%) Commercial n = 5 n (%) In-house n = 23 n (%)  
A 3.9 × 106 + + + 5 (100.0) 5 (100.0) 23 (100.0) 33 (100.0)
B 9.6 × 105 + + + 5 (100.0) 5 (100.0) 22 (95.7) 32 (97.0)
C 8.8 × 104 + + + 5 (100.0) 5 (100.0) 20 (87.0) 30 (90.9)
D 9.4 × 103 + + + 5 (100.0) 5 (100.0) 10 (43.5) 20 (60.6)
E 9.4 × 103 + - + 5 (100.0) 5 (100.0) 9 (39.1) 19 (57.6)
F 7.3 × 102 - - + 2 (40.0) 2 (40.0) 2 (8.7) 6 (18.2)
G 7.3 × 102 - - - 0 (0.0) 1 (20.0) 1 (4.3) 2 (6.1)
H negative - - - 4 (80.0) 5 (100.0) 22 (95.7) 31 (93.9)
I negative - - - 4 (80.0) 4 (80.0) 22 (95.7) 30 (90.9)
  1. 1 Nested PCR in-house on the Applied Biosystems (ABI) GeneAmp PCR System 9700. Sample pre-treatment: thermal shock (Binda et al 2004). Analysis of one punch (3 mm) in triplicate.
  2. 2 Real-time in house PCR on the Applied Biosystems (ABI) ABI PRISM 7900 Sequence Detection System. Sample pre-treatment: QIAGEN DSP kit. UT1: Analysis of three punches (3 mm each), UT2: Analysis of the entire dried blood spot.